Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia

References

• Swerdlow SH, Campo E, Harris NL, WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Herrinton L, Weiss N. Incidence of Waldenstrom's macroglobulinemia. Blood 1993;82:3148–3150.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214–226.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Gertz MA, Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006;133:158–164.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, International prognostic scoring system for Waldenstrom's macroglobulinemia. Blood 2009;113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gertz MA, Kastritis E, Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009;27:120–126.
   PubMed Web of Science ®Google Scholar
• Facon T, Brouillard M, Duhamel A, Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553–1558.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA, Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737–742.
   PubMed Web of Science ®Google Scholar
• Treon SP, Agus DB, Link B, CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001;24:272–279.
   Web of Science ®Google Scholar
• Dimopoulos MA, Zervas C, Zomas A, Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327–2333.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer 2004; 101:2593–2598.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481–1483.
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2008;23:153–161.
   PubMed Web of Science ®Google Scholar
• Ioakimidis L, Patterson C, Hunter Z, Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:62–66.
   PubMedGoogle Scholar
• Delannoy A, Ferrant A, Martiat P, Bosly A, Zenebergh A, Michaux JL. 2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia. Nouv Rev Fr Hematol 1994;36: 317–320.
   PubMedGoogle Scholar
• Dhodapkar MV, Jacobson JL, Gertz MA, Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001;98:41–48.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E, Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195–198.
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Coiffier B, Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546–553.
   PubMed Web of Science ®Google Scholar
• Fridrik MA, Jager G, Baldinger C, Krieger O, Chott A, Bettelheim P. First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie. Ann Hematol 1997;74:7–10.
   PubMed Web of Science ®Google Scholar
• Hellmann A, Lewandowski K, Zaucha JM, Bieniaszewska M, Halaburda K, Robak T. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol 1999;63:35–41.
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer R, Geissler K, Schwarzinger I, Fludarabine therapy in Waldenström's macroglobulinemia. Ann Hematol 2000;79:556–559.
   PubMed Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:243–247.
   PubMed Web of Science ®Google Scholar
• Leblond V, Levy V, Maloisel F, Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Blood 2001;98:2640–2644.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Hamilos G, Efstathiou E, Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44:993–996.
   PubMed Web of Science ®Google Scholar
• Kimby E, Treon SP, Anagnostopoulos A, Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380–383.
   PubMedGoogle Scholar
• Tam CS, Wolf M, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2005;6:136–139.
   PubMedGoogle Scholar
• Tamburini J, Levy V, Chaleteix C, Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia 2005;19:1831–1834.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Miqueleiz S, Ricci F, Fludarabine, cyclophosphamide and rituximab in Waldenstrom's macroglobulinemia: an effective regimen requiring a new category of response criteria and a delayed assessment of results. Blood 2007;110(Suppl. 1): Abstract 1290.
   Google Scholar
• Tedeschi A, Alamos SM, Ricci F, Greco A, Morra E. Fludarabine-based combination therapies for Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:67–70.
   PubMedGoogle Scholar
• Treon SP, Branagan AR, Ioakimidis L, Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Vargaftig J, Pegourie-Bandelier B, Mahe B, Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): results in 25 patients. Haematologica 2007;92(Suppl. 2): Abstract 1226.
   Google Scholar
• Vargaftig J, Pegourie-Bandelier B, Mahe B, Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): results in 21 patients (pts). Blood 2006;108(Suppl. 1): Abstract 4727.
   PubMed Web of Science ®Google Scholar
• Thomas SK, Delasalle K, Gavino M, Wang M, Alexanian R, Weber DM. 2-CDA-cyclophosphamide ± rituximab for symptomatic WM. Haematologica 2007;92(Suppl. 2): Abstract 1227.
   Google Scholar
• Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies. Br J Cancer 1999;79:1215–1219.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Louviaux I, Michaux JL, Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000;14:1136–1142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis M-C, Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344–3349.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG Clinical Trial 05-180. J Clin Oncol 2009;27:3830–3835.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112:4452–4457.
   PubMed Web of Science ®Google Scholar
• Michallet M, Thiébaut A, Dreger P, Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000;108:595–601.
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Cazin B, Lepretre S, Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004;103:363–365.
   PubMed Web of Science ®Google Scholar
• Leleu X, Soumerai J, Roccaro A, Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250–255.
   PubMed Web of Science ®Google Scholar